Dave H, Terpilowski M, Mai M, et al. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2022;6(2):473-485.

Authors:
NA

Journal:
Blood Adv

Publication Year: 2024

DOI:
10.1182/bloodadvances.2023011854

PMCID:
PMC10874894

PMID:
38286747

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Blood Adv

Abbreviation: Blood Adv

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody tre…
Wang L; Leach V; Muthusamy N and 2 more (2024) - Transparency Score: 3/6
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell …
Shree T; Haebe S; Czerwinski DK and 15 more (2024) - Transparency Score: 5/6
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA…
Abou-Ismail MY; Zhang C; Presson AP and 28 more (2024) - Transparency Score: 3/6
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee R; Poh C; Hirayama AV and 9 more (2024) - Transparency Score: 3/6
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymp…
Short NJ; Jabbour E; Jain N and 20 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
16.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025